Journal of Molecular Cell Biology · 2012 · 89 citations · 52 references
Life SciencesImmunologyPathologyAutoimmunityInflammationNeuroimmunologyAutoimmune Disease PathogenesisAutoimmune DiseasesAutoimmune InflammationAutoimmune PathogenesisImmune RegulationInflammatory SignalingCytokine Signaling In AutoimmunityEffector T Cell DifferentiationExperimental Autoimmune EncephalomyelitisImmune Cell HomeostasisImmune Homeostasis RegulationT Cell Differentiation SignalingT Cell-mediated InflammationT-cell Mediated Inflammation
Deficiency in TGF‑β‑induced regulatory T cell differentiation disrupts immune homeostasis and contributes to autoimmune disease, making in‑situ enhancement of iTreg a promising therapeutic strategy. This study investigates how TNF‑α regulates iTreg differentiation and explores TNF‑α antagonism as a novel treatment for autoimmune disease. TNF‑α impairs iTreg differentiation by up‑regulating TNFR2, activating Akt, which binds Smad3 to block its phosphorylation and foxp3 transcription. In experimental autoimmune encephalomyelitis, TNF‑α–mediated suppression of iTreg leads to disease, while TNF‑α neutralization restores iTreg, ameliorates EAE, and this effect is lost when iTreg are depleted, confirming a selective, TNF‑α‑dependent pathway.
Deficiency in the TGF-β-induced regulatory T (iTreg) cell differentiation is associated with compromised immune homeostasis and plays a key role in many autoimmune diseases. Therapeutic intervention to enhance in situ iTreg differentiation has become a promising treatment modality for autoimmune diseases. Here we describe that the development of autoimmune inflammation in experimental autoimmune encephalomyelitis (EAE) is associated with selective impairment of iTreg differentiation largely due to the increased production of TNF-α. The neutralization of TNF-α markedly increases iTreg differentiation, leading to the amelioration of EAE, whereas the depletion of iTreg cells abolishes the therapeutic effect of an anti-TNF-α antibody. The inhibition of iTreg differentiation by TNF-α is mediated through a signaling cascade involving the induction of TNF receptor II (TNFR2) expression and the activation of Akt. The activated Akt in turn interacts with Smad3, resulting in the inhibition of TGF-β-induced Smad3 phosphorylation and consequently the reduction of p-Smad3 results in the decreased binding to the specific binding site of the foxp3 promoter, and finally foxp3 transcription itself. Interestingly, this regulatory pathway is iTreg cell specific as TNF-α does not activate Akt in naturally occurring regulatory T cells, therefore conferring a selective effect of TNF-α and its antagonism on iTreg cells. The study sheds new light on the critical role and underlying mechanism of TNF-α in the regulation of iTreg differentiation and provides a novel rationale for TNF-α antagonistic therapy for autoimmune diseases.
52
WanJun Chen, Wenwen Jin, Neil J. Hardegen et al. · The Journal of Experimental Medicine · 2003 · 4.6K citations · Full text
Simon Read, Vivianne Malmström, Fiona Powrie · The Journal of Experimental Medicine · 2000 · 2.2K citations